
Jianying Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2506368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ, The, 2020, 369, m1443.	6.0	1,226
2	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 305-314.	10.7	277
3	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 867-875.	1.1	260
4	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQqO	0 ûr gBT /	Ovzer4ock 10
5	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1405-1411.	1.6	230
6	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). British Journal of Cancer, 2018, 118, 654-661.	6.4	192
7	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respiratory Medicine,the, 2019, 7, 437-446.	10.7	192
8	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer. JAMA Oncology, 2021, 7, 709.	7.1	185
9	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.7 8. 1132-1143.	'84314 rgE 10.7	BT / Overlock
10	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 2021, 16, 1501-1511.	1.1	158
11	Results of PROFILE 1029, a Phase III Comparison ofÂFirst-Line Crizotinib versus Chemotherapy inÂEast Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1539-1548.	1.1	146
12	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1512-1522.	1.1	127
13	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2021, 397, 499-509.	13.7	119
14	Genomic Analysis of the Multidrug-Resistant Acinetobacter baumannii Strain MDR-ZJ06 Widely Spread in China. Antimicrobial Agents and Chemotherapy, 2011, 55, 4506-4512.	3.2	116
15	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respiratory Medicine,the, 2021, 9, 1154-1164.	10.7	107
16	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 45-53.	10.7	105
17	Icotinib versus chemotherapy as adjuvant treatment for stage Il–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1021-1029.	10.7	93
18	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	1.1	85

#	Article	IF	CITATIONS
19	Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Critical Care, 2020, 24, 299.	5.8	85
20	Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunology, Immunotherapy, 2021, 70, 619-631.	4.2	80
21	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations. Journal of Clinical Oncology, 2022, 40, 3162-3171.	1.6	76
22	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Journal of Thoracic Oncology, 2021, 16, 2109-2120.	1.1	75
23	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. Journal of Thoracic Oncology, 2021, 16, 299-309.	1.1	72
24	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. Journal of Thoracic Oncology, 2022, 17, 411-422.	1.1	70
25	Secondary Bacterial Infections in Critical III Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2020, 7, ofaa220.	0.9	66
26	The Overexpression of Heparin-Binding Epidermal Growth Factor Is Responsible for Th17-Induced Airway Remodeling in an Experimental Asthma Model. Journal of Immunology, 2010, 185, 834-841.	0.8	65
27	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PDâ€L1â€positive locally advanced or metastatic non–smallâ€cell lung cancer: KEYNOTEâ€042 China Study. International Journal of Cancer, 2021, 148, 2313-2320.	5.1	60
28	Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. Journal of Medical Microbiology, 2015, 64, 702-707.	1.8	58
29	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. Journal of Thoracic Oncology, 2020, 15, 1015-1026.	1.1	58
30	First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder. Journal of Affective Disorders, 2020, 277, 337-340.	4.1	56
31	Characterization of a Novel Plasmid Type and Various Genetic Contexts of blaOXA-58 in Acinetobacter spp. from Multiple Cities in China. PLoS ONE, 2014, 9, e84680.	2.5	52
32	High Prevalence of ESBL-Producing Klebsiella pneumoniae Causing Community-Onset Infections in China. Frontiers in Microbiology, 2016, 7, 1830.	3.5	50
33	Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia. Medicine (United States), 2019, 98, e14937.	1.0	50
34	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+) Journal of Clinical Oncology, 2020, 38, 9519-9519.	1.6	50
35	Clinical and Radiographic Characteristics of Pulmonary Nocardiosis: Clues to Earlier Diagnosis. PLoS ONE, 2014, 9, e90724.	2.5	49
36	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. Signal Transduction and Targeted Therapy, 2021, 6, 355.	17.1	45

#	Article	IF	CITATIONS
37	Clinical Impact of Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage in the Diagnosis and Management of Pneumonia. Journal of Molecular Diagnostics, 2021, 23, 1259-1268.	2.8	43
38	Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening. PLoS ONE, 2014, 9, e92828.	2.5	42
39	Dioscin elicits antiâ€ŧumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 9217-9230.	3.6	42
40	The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199296.	3.2	40
41	Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. BMC Cancer, 2017, 17, 161.	2.6	38
42	Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer. Cancer Letters, 2017, 408, 130-137.	7.2	37
43	TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. Oncotarget, 2016, 7, 29620-29634.	1.8	32
44	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 32-37.	2.0	32
45	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations Journal of Clinical Oncology, 2021, 39, 9008-9008.	1.6	30
46	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations. Cancer Discovery, 2022, 12, 1676-1689.	9.4	30
47	VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Letters, 2021, 522, 142-154.	7.2	29
48	Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. BMC Cancer, 2018, 18, 10.	2.6	28
49	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 989-999.	2.8	28
50	Clinical Analysis of Percutaneous Computed Tomography–Guided Hook Wire Localization of 168 Small Pulmonary Nodules. Annals of Thoracic Surgery, 2015, 100, 1861-1867.	1.3	27
51	Dioscin facilitates ROS-induced apoptosis via the p38-MAPK/HSP27-mediated pathways in lung squamous cell carcinoma. International Journal of Biological Sciences, 2020, 16, 2883-2894.	6.4	27
52	Current small cell lung cancer treatment in <scp>C</scp> hina. Thoracic Cancer, 2015, 6, 233-238.	1.9	26
53	IL-17A-producing T cells are associated with the progression of lung adenocarcinoma. Oncology Reports, 2016, 36, 641-650.	2.6	26
54	Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 3513-3524.	4.2	26

#	Article	IF	CITATIONS
55	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. Journal of Thoracic Oncology, 2021, 16, 1403-1414.	1.1	26
56	Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis. Oncology Reports, 2015, 33, 478-484.	2.6	24
57	IL-17A, But Not IL-17F, Is Indispensable for Airway Vascular Remodeling Induced by Exaggerated Th17 Cell Responses in Prolonged Ovalbumin-Challenged Mice. Journal of Immunology, 2015, 194, 3557-3566.	0.8	23
58	Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1. International Journal of Biological Sciences, 2016, 12, 850-860.	6.4	23
59	<scp>FGF</scp> 19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. Thoracic Cancer, 2017, 8, 655-665.	1.9	23
60	SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. Oncotarget, 2018, 9, 10891-10904.	1.8	23
61	HB-EGF–Promoted Airway Smooth Muscle Cells and Their Progenitor Migration Contribute to Airway Smooth Muscle Remodeling in Asthmatic Mouse. Journal of Immunology, 2016, 196, 2361-2367.	0.8	21
62	A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. Oncology Letters, 2015, 10, 1575-1578.	1.8	20
63	Deguelin Attenuates Allergic Airway Inflammation via Inhibition of NF-κb Pathway in Mice. International Journal of Biological Sciences, 2017, 13, 492-504.	6.4	20
64	Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study. Journal of Thoracic Disease, 2017, 9, 5068-5074.	1.4	20
65	Interleukin-10 Promoter Gene Polymorphisms and Susceptibility to Tuberculosis: A Meta-Analysis. PLoS ONE, 2015, 10, e0127496.	2.5	19
66	Epithelial‑mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC. Molecular Medicine Reports, 2019, 19, 601-608.	2.4	19
67	Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Letters, 2018, 436, 1-9.	7.2	18
68	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	2.0	18
69	Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. BMC Pulmonary Medicine, 2015, 15, 20.	2.0	17
70	Association between Tumor Necrosis Factor-α rs1800629 Polymorphism and Risk of Asthma: A Meta-Analysis. PLoS ONE, 2014, 9, e99962.	2.5	16
71	Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, China. Infectious Microbes & Diseases, 2020, 2, 55-63.	1.3	16
72	Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 680191.	2.8	16

#	Article	IF	CITATIONS
73	Combination of Tigecycline and Levofloxacin for Successful Treatment of Nosocomial Pneumonia Caused by New Delhi Metallo-β-Lactamase-1-Producing <i>Raoultella planticola</i> . Microbial Drug Resistance, 2017, 23, 127-131.	2.0	15
74	Bloodstream Infections due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : A Single-Center Retrospective Study on Risk Factors and Therapy Options. Microbial Drug Resistance, 2021, 27, 227-233.	2.0	15
75	Advanced lung adenocarcinomas with <i>ROS1</i> -rearrangement frequently show hepatoid cell. Oncotarget, 2016, 7, 74162-74170.	1.8	15
76	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. Journal of Thoracic Oncology, 2022, 17, 816-826.	1.1	15
77	<p>New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation</p> . International Journal of COPD, 2019, Volume 14, 1119-1125.	2.3	14
78	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. PLoS ONE, 2015, 10, e0142500.	2.5	14
79	Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. Thoracic Cancer, 2015, 6, 216-219.	1.9	13
80	Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2â€FGFR1 autocrine loop. Cancer Medicine, 2018, 7, 6205-6218.	2.8	13
81	Virulence and genomic features of a bla _{CTX-M-3} and bla _{CTX-M-14} coharboring hypermucoviscous Klebsiella pneumoniae of serotype K2 and ST65. Infection and Drug Resistance, 2019. Volume 12. 145-159.	2.7	13
82	Emergence of transferable ceftazidime–avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China. Clinical Microbiology and Infection, 2022, 28, 136.e1-136.e6.	6.0	13
83	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non‒Small-Cell Lung Cancer in KEYNOTE-407. JTO Clinical and Research Reports, 2021, 2, 100225.	1.1	13
84	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. PLoS ONE, 2015, 10, e0136659.	2.5	13
85	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. Lung Cancer, 2020, 146, 252-262.	2.0	12
86	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget, 2017, 8, 66293-66304.	1.8	11
87	Microbiological and clinical characteristics of cryptococcemia: a retrospective analysis of 85 cases in a Chinese hospital. Medical Mycology, 2020, 58, 478-484.	0.7	11
88	Metagenomic sequencing with spiked-in internal control to monitor cellularity and diagnosis of pneumonia. Journal of Infection, 2022, 84, e13-e17.	3.3	11
89	Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of Thoracic Oncology, 2022, 17, 708-717.	1.1	11
90	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer, 2020, 150, 240-246.	2.0	10

#	Article	lF	CITATIONS
91	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC Journal of Clinical Oncology, 2017, 35, 9053-9053.	1.6	10
92	IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway. American Journal of Physiology - Cell Physiology, 2022, 322, C814-C824.	4.6	10
93	Particulate matter with a diameter of â‰Ձ.5 μm induces and enhances bleomycin-induced pulmonary fibrosis by stimulating endoplasmic reticulum stress in rat. Biochemistry and Cell Biology, 2019, 97, 357-363.	2.0	9
94	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. Journal of Thoracic Disease, 2014, 6, 958-64.	1.4	9
95	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study. Clinical Cancer Research, 2022, 28, 1127-1135.	7.0	9
96	Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report. Frontiers in Oncology, 2021, 11, 760097.	2.8	9
97	Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events. Frontiers in Oncology, 2021, 11, 757069.	2.8	9
98	Regulation of Viral Infection-induced Airway Remodeling Cytokine Production by the TLR3-EGFR Signaling Pathway in Human Bronchial Epithelial Cells. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 750-755.	1.6	8
99	Evaluation of a quantitative serum <i>Aspergillus fumigatus</i> â€specific IgM assay for diagnosis of chronic pulmonary aspergillosis. Clinical Respiratory Journal, 2018, 12, 2566-2572.	1.6	8
100	Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. Lung Cancer, 2020, 147, 130-136.	2.0	8
101	Analysis of clinical characteristics and prognosis of talaromycosis (with or without human) Tj ETQq1 1 0.78431	4 rgBT /Ov	erlock 10 Tf 3
102	Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China. Respiratory Medicine, 2021, 186, 106522.	2.9	8
103	A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis Journal of Clinical Oncology, 2020, 38, e21618-e21618.	1.6	8
104	A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features. PLoS ONE, 2016, 11, e0161861.	2.5	8
105	Linezolid combined with trimethoprim–sulfamethoxazole therapy for the treatment of disseminated nocardiosis. Journal of Medical Microbiology, 2011, 60, 1043-1045.	1.8	7
106	A potential target gene for the host-directed therapy of mycobacterial infection in murine macrophages. International Journal of Molecular Medicine, 2016, 38, 823-833.	4.0	7
107	Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature. Immunotherapy, 2020, 12, 957-964.	2.0	7
108	Predicting Survival Across Acute Exacerbation of Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myositis: The GAP-ILD Model. Rheumatology and Therapy, 2020, 7, 967-978.	2.3	7

#	Article	IF	CITATIONS
109	Triptolide induces atrophy of myotubes by triggering IRS-1 degradation and activating the FoxO3 pathway. Toxicology in Vitro, 2020, 65, 104793.	2.4	7
110	Loss of LIMCH1 predicts poor prognosis in patients with surgically resected Lung Adenocarcinoma: A study based on Immunohistochemical Analysis and Bioinformatics. Journal of Cancer, 2021, 12, 181-189.	2.5	7
111	Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019. Journal of Medical Virology, 2021, 93, 4446-4453.	5.0	7
112	Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Translational Lung Cancer Research, 2021, 10, 1819-1828.	2.8	7
113	Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases. Frontiers in Oncology, 2021, 11, 619371.	2.8	7
114	Phase 3 study of first-line crizotinib vs pemetrexedâ^'cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i> + advanced non-squamous non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, 9058-9058.	1.6	7
115	Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget, 2016, 7, 63758-63766.	1.8	7
116	Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. Signal Transduction and Targeted Therapy, 2021, 6, 374.	17.1	7
117	Serum <i>Aspergillus fumigatus</i> â€specific IgG antibody decreases after antifungal treatment in chronic pulmonary aspergillosis patients. Clinical Respiratory Journal, 2018, 12, 1772-1774.	1.6	6
118	Hypoxiaâ€ʻinducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib. Oncology Letters, 2019, 17, 4034-4043.	1.8	6
119	Clinical Characteristics of Chronic Lung Abscess Associated with Parvimonas micra Diagnosed Using Metagenomic Next-Generation Sequencing. Infection and Drug Resistance, 2021, Volume 14, 1191-1198.	2.7	6
120	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	2.8	6
121	Culture-Related Health Disparities in Quality of Life: Assessment of Instrument Dimensions Among Chinese. Frontiers in Public Health, 2021, 9, 663904.	2.7	6
122	The characteristic of asthma control among nasal diseases population: Results from a cross-sectional study. PLoS ONE, 2018, 13, e0191543.	2.5	6
123	Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer. Journal of Immunology Research, 2022, 2022, 1-12.	2.2	6
124	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures Journal of Clinical Oncology, 2022, 40, 9015-9015.	1.6	6
125	>Discovery of a Novel Hypervirulent Acinetobacter baumannii Strain in a Case of Community-Acquired Pneumonia. Infection and Drug Resistance, 2020, Volume 13, 1147-1153.	2.7	5
126	Gremlin2 Activates Fibroblasts to Promote Pulmonary Fibrosis Through the Bone Morphogenic Protein Pathway. Frontiers in Molecular Biosciences, 2021, 8, 683267.	3.5	5

#	Article	IF	CITATIONS
127	Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC) Journal of Clinical Oncology, 2019, 37, 9091-9091.	1.6	5
128	SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study Journal of Clinical Oncology, 2020, 38, e21689-e21689.	1.6	5
129	Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients. Oncotarget, 2017, 8, 108840-108847.	1.8	5
130	ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis. Cell Cycle, 2021, 20, 2607-2618.	2.6	5
131	Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?. Lancet Oncology, The, 2013, 14, e438.	10.7	4
132	Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review. Oncology Letters, 2015, 9, 2041-2045.	1.8	4
133	Diffuse alveolar hemorrhage due to metastatic angiosarcoma of the lung: A case report. Oncology Letters, 2015, 10, 3853-3855.	1.8	4
134	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment. Medicine (United States), 2021, 100, e23712.	1.0	4
135	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <i>MET exon 14</i> skipping alterations (<i>METex14</i>). Cancer Research, 2021, 81, CT158-CT158.	0.9	4
136	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial Journal of Clinical Oncology, 2012, 30, 7559-7559.	1.6	4
137	Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Journal of Clinical Oncology, 2020, 38, 9554-9554.	1.6	4
138	Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials. International Journal of Clinical and Experimental Medicine, 2015, 8, 19689-700.	1.3	4
139	Asthma Management Using the Mobile Asthma Evaluation and Management System in China. Allergy, Asthma and Immunology Research, 2022, 14, 85.	2.9	4
140	Overexpression of KIAA0101 Promotes the Progression of Non-small Cell Lung Cancer. Journal of Cancer, 2020, 11, 6663-6674.	2.5	3
141	First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 509-519.e1.	2.6	3
142	Efficacy of different antifungal drugs as initial treatment for patients with talaromycosis: A systematic review and meta-analysis. Journal De Mycologie Medicale, 2021, 31, 101108.	1.5	3
143	HIV-negative case of Talaromyces marneffei pulmonary infection with a TSC2 mutation. Journal of International Medical Research, 2021, 49, 030006052110167.	1.0	3
144	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). Cancer Research, 2021, 81, CT041-CT041.	0.9	3

#	Article	IF	CITATIONS
145	Deguelin Attenuates Non-Small-Cell Lung Cancer Cell Metastasis by Upregulating PTEN/KLF4/EMT Signaling Pathway. Disease Markers, 2022, 2022, 1-10.	1.3	3
146	Primary pulmonary chondrosarcoma and a fast-growing mass that accidentally mimicked teratoma. Journal of Thoracic Disease, 2016, 8, E947-E951.	1.4	2
147	Template-ready PCR method for detection of human telomerase reverse transcriptase mRNA in sputum. Analytical Biochemistry, 2019, 577, 34-41.	2.4	2
148	Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, e150-e153.	1.1	2
149	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Lung Cancer, 2020, 146, 209-216.	2.0	2
150	A Case of Small Cell Lung Carcinoma Harboring an EML4–ALK Fusion with Partial Response to Crizotinib. Clinical Lung Cancer, 2021, 22, e799-e803.	2.6	2
151	RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 Journal of Clinical Oncology, 2021, 39, 9102-9102.	1.6	2
152	Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion Journal of Clinical Oncology, 2013, 31, e22054-e22054.	1.6	2
153	Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501) Journal of Clinical Oncology, 2016, 34, TPS8570-TPS8570.	1.6	2
154	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 3344-8.	0.5	2
155	Benzo[a]pyrene inhibits myoblast differentiation through downregulating the Hsp70-MK2-p38MAPK complex. Toxicology in Vitro, 2022, 82, 105356.	2.4	2
156	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With <i>EGFR</i> Mutation-Positive NSCLC. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211032.	1.3	2
157	SAF-189s in advanced, ALK-positive, non–small cell lung cancer: Results from a first-in-human phase 1/2, multicenter study Journal of Clinical Oncology, 2022, 40, 9076-9076.	1.6	2
158	Abstract CT538: Tepotinib + gefitinib in patients with <i>EGFR</i> -mutant NSCLC with <i>MET</i> amplification: Final analysis of INSIGHT. Cancer Research, 2022, 82, CT538-CT538.	0.9	2
159	Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia. Oncology Research, 2017, 25, 545-550.	1.5	1
160	Sec3 knockdown inhibits TGF-β induced epithelial-mesenchymal transition through the down-regulation of Akt phosphorylation in A549 cells. Biochemical and Biophysical Research Communications, 2019, 519, 253-260.	2.1	1
161	A novel stilbene derivative (GMQ3) suppressed proliferation and induced apoptosis in lung cancer via the p38-MAPK/SIRT1 pathway. Biochemical Pharmacology, 2021, 193, 114808.	4.4	1
162	Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas. Oncology Letters, 2020, 20, 2987-2996.	1.8	1

#	Article	IF	CITATIONS
163	TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer. Frontiers in Genetics, 2022, 13, .	2.3	1
164	Phase I study of the efficacy and safety of IBI319 in patients with advanced malignant tumors Journal of Clinical Oncology, 2022, 40, 2646-2646.	1.6	1
165	Hyperlipidemia Caused by Voriconazole: A Case Report. Infection and Drug Resistance, 2021, Volume 14, 483-487.	2.7	0
166	Allergic Bronchopulmonary Mycosis Caused by Mucor Overlapping With Invasive Pulmonary Mucormycosis: A Case Report. Frontiers in Medicine, 2022, 9, 831213.	2.6	0
167	Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years. Cancer Research, 2022, 82, CT552-CT552.	0.9	0
168	Abstract CT555: Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study. Cancer Research, 2022, 82, CT555-CT555.	0.9	0